Article (Périodiques scientifiques)
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.
Kwon, Janice S; McTaggart-Cowan, Helen; Ferguson, Sarah E et al.
2024In Journal of Gynecologic Oncology, 35 (6), p. 117
Peer reviewed vérifié par ORBi
 

Documents


Texte intégral
2024-JGO-Cervix-Shape-Cost Effectiveness-Kwon.pdf
Postprint Auteur (2.64 MB)
Télécharger

Tous les documents dans ORBi sont protégés par une licence d'utilisation.

Envoyer vers



Détails



Mots-clés :
Cost-Effectiveness; Early Stage Cervical Cancer; Health Utility; Low Risk; Quality-Adjusted Life Expectancy; Radical Hysterectomy; Simple Hysterectomy; Humans; Female; Middle Aged; Quality of Life; Adult; Neoplasm Recurrence, Local; Neoplasm Staging; Cost-Effectiveness Analysis; Uterine Cervical Neoplasms/surgery; Uterine Cervical Neoplasms/economics; Uterine Cervical Neoplasms/pathology; Hysterectomy/methods; Hysterectomy/economics; Cost-Benefit Analysis; Quality-Adjusted Life Years; Markov Chains; Hysterectomy; Uterine Cervical Neoplasms; Oncology; Obstetrics and Gynecology
Résumé :
[en] [en] OBJECTIVE: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for quality of life and sexual health. The objective was to conduct a cost-effectiveness analysis comparing simple vs. radical hysterectomy for low-risk early-stage cervical cancer. METHODS: Markov model compared the costs and benefits of simple vs. radical hysterectomy for early cervical cancer over a 5-year time horizon. Quality-adjusted life years (QALYs) were estimated from health utilities derived from EQ-5D-3L surveys. Sensitivity analyses accounted for uncertainty around key parameters. Monte Carlo simulation estimated complication numbers according to surgical procedure. RESULTS: Simple hysterectomy was more effective and less costly than radical hysterectomy. Average overall costs were $11,022 and $12,533, and average gains were 3.56 and 3.54 QALYs for simple and radical hysterectomy, respectively. Baseline health utility scores were 0.81 and 0.83 for simple and radical hysterectomy, respectively. By year 3, these scores improved for simple hysterectomy (0.82) but not for radical hysterectomy (0.82). Assuming 800 early cervical cancer patients annually in Canada, the model estimated 3 vs. 82 patients with urinary retention, and 49 vs. 86 patients with urinary incontinence persisting 4 weeks after simple vs. radical hysterectomy, respectively. Results were most sensitive to variability in health utilities after surgery, but stable through wide ranges of costs and recurrence estimates. CONCLUSION: Simple hysterectomy is less costly and more effective in terms of quality-adjusted life expectancy compared to radical hysterectomy for early cervical cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01658930.
Disciplines :
Oncologie
Médecine de la reproduction (Gynécologie, andrologie, obstétrique)
Sciences de la santé humaine: Multidisciplinaire, généralités & autres
Auteur, co-auteur :
Kwon, Janice S ;  University of British Columbia, Vancouver, Canada. Janice.Kwon@vch.ca
McTaggart-Cowan, Helen ;  BC Cancer, Vancouver, Canada
Ferguson, Sarah E ;  Princess Margaret Cancer Centre, Toronto, Canada
Samouëlian, Vanessa ;  Centre Hospitalier de l'Université de Montréal, Montréal, Canada
Lambaudie, Eric ;  Institut Paoli-Calmettes, Marseille, France
Guyon, Frédéric ;  Institut Bergonie, Bordeaux, France
Tidy, John ;  Royal Hallamshire Hospital, Sheffield, United Kingdom
Williamson, Karin ;  Nottingham University Hospitals, Nottingham, United Kingdom
Gleeson, Noreen ;  St James' Hospital, Dublin, Ireland
de Kroon, Cor ;  Leiden University Medical Center, Leiden, Netherlands
van Driel, Willemien ;  Netherlands Cancer Institute, Amsterdam, Netherlands
Mahner, Sven ;  LMU University Hospital, Munich, Germany
Hanker, Lars ;  University Hospital Schleswig-Holstein, Lubeck, Germany
Goffin, Frédéric  ;  Université de Liège - ULiège > Département des sciences cliniques
Berger, Regina ;  Medical University Innsbruck, Innsbruck, Austria
Eyjólfsdóttir, Brynhildur ;  The Norwegian Radium Hospital, Oslo, Norway
Kim, Jae-Weon ;  Seoul National University College of Medicine, Seoul, Korea
Brotto, Lori A ;  University of British Columbia, Vancouver, Canada
Pataky, Reka ;  BC Cancer, Vancouver, Canada
Yeung, Shirley S T ;  BC Cancer, Vancouver, Canada
Chan, Kelvin K W ;  Sunnybrook Health Sciences Centre and Odette Cancer Centre, University of Toronto, Canada
Cheung, Matthew C ;  Sunnybrook Health Sciences Centre and Odette Cancer Centre, University of Toronto, Canada
Ubi, Juliana;  Canadian Cancer Trials Group, Queen's University, Kingston, Canada
Tu, Dongsheng ;  Canadian Cancer Trials Group, Queen's University, Kingston, Canada
Shepherd, Lois E ;  Canadian Cancer Trials Group, Queen's University, Kingston, Canada
Plante, Marie ;  Centre Hospitalier Universitaire de Québec, Québec, Canada
Plus d'auteurs (16 en +) Voir moins
Langue du document :
Anglais
Titre :
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.
Date de publication/diffusion :
novembre 2024
Titre du périodique :
Journal of Gynecologic Oncology
ISSN :
2005-0380
eISSN :
2005-0399
Maison d'édition :
Korean Society of Gynecologic Oncology and Colposcopy, Korea south
Volume/Tome :
35
Fascicule/Saison :
6
Pagination :
e117
Peer reviewed :
Peer reviewed vérifié par ORBi
Organisme subsidiant :
CIHR - Canadian Institutes of Health Research
Subventionnement (détails) :
Canadian Cancer Trials Group (CCTG) for operational support and the Canadian Institutes of Health Research (CIHR) for research funding.JSK discloses research funding from Michael Smith Health Research BC (formerly Michael Smith Foundation for Health Research),ownership of shares from Hexamer Therapeutics, and speaker fee from Astra Zeneca. MP discloses research funding from Astra Zeneca, royalties from UpToDate, and serving as an Advisory Board member for Serono-Merck.
Disponible sur ORBi :
depuis le 26 décembre 2024

Statistiques


Nombre de vues
93 (dont 1 ULiège)
Nombre de téléchargements
28 (dont 0 ULiège)

citations Scopus®
 
5
citations Scopus®
sans auto-citations
3
OpenCitations
 
0
citations OpenAlex
 
7

Bibliographie


Publications similaires



Contacter ORBi